AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexfenfluramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 832 | 3239-44-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.85 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 61 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 11 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.66 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 14 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 26.77 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CG,PRKDC,TEK,TGFBR1 | 24 | |||
| kinase-selectivity-class | AXL,EIF2AK3,EPHB4,PDK4 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1970 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AA04 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:50507 | appetite depressant |
| CHEBI has role | CHEBI:50949 | serotonin uptake inhibitor |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
Related Drugs by ATC class:
A08AA Centrally acting antiobesity products 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obesity | indication | 414916001 | DOID:9970 |
| Alcoholism | contraindication | 7200002 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1A adrenergic receptor | GPCR | Ki | 6.57 | WOMBAT-PK | |||||
| Beta-1 adrenergic receptor | GPCR | Ki | 6.00 | PDSP | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.28 | PDSP | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.66 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.18 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.08 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.61 | PDSP | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.38 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.79 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.04 | PDSP | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 5.26 | PDSP | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.62 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.73 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.58 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.33 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.16 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.72 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 5.90 | PDSP | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.71 | PDSP | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.85 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.47 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024029 | VUID |
| N0000022034 | NUI |
| D03713 | KEGG_DRUG |
| 155142 | RXNORM |
| 4020972 | VANDF |
| 4024029 | VANDF |
| C0011786 | UMLSCUI |
| CHEBI:439329 | CHEBI |
| CHEMBL248702 | ChEMBL_ID |
| DB01191 | DRUGBANK_ID |
| CHEMBL1887891 | ChEMBL_ID |
| D020372 | MESH_DESCRIPTOR_UI |
| 66265 | PUBCHEM_CID |
| 5818 | INN_ID |
| 3239-45-0 | SECONDARY_CAS_RN |
| E35R3G56OV | UNII |
| DB00574 | DRUGBANK_ID |
| 4557 | MMSL |
| d04006 | MMSL |
| 004127 | NDDF |
| 004128 | NDDF |
| 322047008 | SNOMEDCT_US |
| 412366002 | SNOMEDCT_US |
Pharmaceutical products:
None